ClinicalTrials.gov
public full text
Public Domain
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women#1138877
- A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis#995299
- Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis#915002
- Lubricant Investigation in Men to Inhibit Transmission of HPV Infection#1114257
- Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)#1125039
Record · ID 1151320
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive